Gatti, Milo http://orcid.org/0000-0003-3018-3779
Pea, Federico http://orcid.org/0000-0002-6966-7167
Article History
Accepted: 11 January 2021
First Online: 30 January 2021
Declarations
:
: This editorial was not funded in whole or in part by any research grant or funding body.
: Federico Pea participated in speaker bureaux for Angelini, Basilea Pharmaceutica, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Pfzer, and Sanof Aventis, and in advisory boards for Angelini, Basilea Pharmaceutica, Correvio, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Novartis, Pfzer, Shionogi, and Thermo-Fisher. Milo Gatti has no conflicts of interest that are directly relevant to the content of this editorial.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MG made substantial contributions to the conception of the manuscript. MG was involved in drafting the manuscript. FP made substantial contributions in critically revising the manuscript for important intellectual content. Both authors approved the final version of the manuscript.
Free to read: This content has been made available to all.